Human Influenza
Conditions
Keywords
Respiratory Tract Infections; Orthomyxoviridae Infections
Brief summary
Phase III clinical trial was carried out in Jintan city, Jiangsu Province, China in May, 2006. Trial results showed that the vaccine had proved safety and immunogenicity. Influenza vaccine of Hualanbio has obtained production permission and marketing authorization in May, 2008. In order to further investigate the safety and immunogenicity of the vaccine in the market, The clinical observation was planned to be conducted in Mianyang city (Yanting County), Sichuan Province, China.
Detailed description
Dosage and administration route in this clinical trial: Subjects age 3 years or older was vaccinated following a single 0.5ml dose immunization regime. The preferred site of injection was the at the skin near outboard deltoid muscle of the upper arm. The administration route is after the sanitization with 75% alcohol, intramuscularly inject the test vaccine or the control vaccines when the skin was slightly dried for those subjects complied with the inclusion requirements. Safety indicators: * Post-vaccination local and systemic adverse reaction levels, together with the soliciting adverse reaction within 30 minutes ; * Post-vaccination local and systemic adverse reaction levels, together with the soliciting adverse reactions through 6 hours to the 29th day ; * Summarize the adverse events/severe adverse events and the incidence levels from the inclusion of the subjects to the completion of the clinical trial. Immunogenicity indicators: Evaluate the Post-vaccination immunogenicity of the test and the control influenza vaccines in persons age 3 years and older by its HI antibody level on Day 28. Take 1:10 serum dilution as the minimum dilutability. The seroconversion in this trial was defined as the post-vaccination HI antibody titer ≥ 1:40 when the HI antibody \< 1:10 before the vaccination or the post-vaccination HI antibody titer quadruply increased when HI antibody ≥ 1:10 before the vaccination. The Immunogenicity criteria set for this clinical trial is the seroconversion shall be \> 40% after 14 days of the vaccination.
Interventions
BIOLOGICALInactivated Influenza Vaccine
200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
BIOLOGICALInactivated Influenza Vaccine of Pasteur
200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
BIOLOGICALInactivated Influenza Vaccine of GSK
200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
Sponsors
Hualan Biological Engineering, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female age 3 and older, volunteers or their guardians are able to understand and sign the informed consent; * Healthy male or female by inquiring illness history, physical examination and clinical judgment and who complies with vaccination of this product; * Be able to comply with the requirement of clinical trial protocol; * Have no history of vaccination within the past 6 months and vaccination with other product within the latest 1 week; * Axillary temperature \<37.1℃.
Exclusion criteria
* Subject that was allergic to eggs and any component of the vaccine, or has history of other allergy; * Fever, acute disease or acute onset of chronic disease and influenza; * Guillain-Barre Syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with adverse reactions as a measure of safety study | 28 days after the vaccination | Local reactions, systemic reactions, severity degree and AEFI correlation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Observation of the immunological effect | 28 days after the immunization | HI antibody seroconversion ratios |
Countries
China
Outcome results
None listed